Targeting malignant glioma cells in vitro using platelet-derived growth factor AA-based conjugates

Journal of Drug Targeting

Volumn 17, Issue 4, 2009, Pages 268-277

  Wester, Maria Dahlström ^a   Wasteson, Åke ^a   Lindstr Öm, Annelie ^a  

^a LINKÖPING UNIVERSITY   (Sweden)

Author keywords

Conjugate; Dextran; Glioblastoma multiforme; PDGF receptors; PDGFAA; Targeting

Indexed keywords

DEXTRAN; IODINE 125; LIGAND; PLATELET DERIVED GROWTH FACTOR AA;

ARTICLE; CONTROLLED STUDY; DRUG CONJUGATION; DRUG TARGETING; GLIOBLASTOMA; HUMAN; HUMAN CELL; IN VITRO STUDY; ISOTOPE LABELING; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIOACTIVITY;

CELL LINE, TUMOR; DEXTRANS; DRUG DELIVERY SYSTEMS; GENE EXPRESSION; GLIOMA; HUMANS; IODINE RADIOISOTOPES; PLATELET-DERIVED GROWTH FACTOR; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA; TYROSINE;

EID: 70350204852     PISSN: 1061186X     EISSN: 10292330     Source Type: Journal    
DOI: 10.1080/10611860902718698     Document Type: Article

References (43)

1. Alper Arslan M, Kutuk O, Basaga H. (2006). Protein kinases as drug targets in cancer. Curr Cancer Drug Targets. 6:623-634.
2. Andersson A, Holmberg A, Carlsson J, Pontén J, Westermark B. (1991). Binding of epidermal growth factor-dextran conjugates to cultured glioma cells. Int J Cancer, 47, 439-444.
3. Andersson A, Capala J, Carlsson J. (1992). Effects of EGF-dextrantyrosine- 131I conjugates on the clonogenic survival of cultured glioma cells. J Neurooncol, 14, 213-223.
4. Axén R, Porath J, Ernback S. (1967). Chemical coupling of peptides and proteins to polysaccharides by means of cyanogens halides. Nature, 214, 1302-1304.
5. Board R, Jayson GC. (2005). Platelet-derived growth factor receptor (PDGFR): A target for anticancer therapeutics. Drug Resist Updat, 8, 75-83.
6. Chandana SR, Movva S, Arora M, Singh T. (2008). Primary brain tumors in adults. Am Fam Physician, 77, 1423-1430.
7. Claesson-Welsh L, Hammacher A, Westermark B, Heldin C-H, Nistér M. (1989). Identification and structural analysis of the A type receptor for platelet-derived growth factor. J Biol Chem, 264, 1742-1747.
8. Colman H, Aldape K. (2008). Molecular predictors in glioblastoma. Towards personalized therapy. Arch Neurol, 65, 877-883.
9. Dahlström M, Capala J, Lindström P, Wasteson Å, Lindström A. (2004). Accumulation of boron in human malignant glioma cells in vitro is cell type dependent. J Neurooncol, 68, 199-205.
10. Dai C, Celestino JC, Okada Y, Louis DN, Fuller GN, Holland EC. (2001). PDGF autocrine stimulation dedifferentiates cultured astrocytes and induces oligodendrogliomas and oligoastrocytomas from neural progenitors and astrocytes in vivo. Genes Dev, 15, 1913-1925.
11. Debinski W. (2008). Drug cocktails for effective treatment of glioblastoma multiforme. Expert Rev NeuroTher, 8, 515-517.
12. Francis GE, Delgado C, Fischer D, Malik F, Agrawal AK. (1996). Polyethylene glycol modification. Relevance and improved methodology to tumour targeting. J Drug Target, 3, 321-340.
13. George D. (2003). Targeting PDGF receptors in cancer-rationales and proof of concept clinical trials. Adv Exp Med Biol, 532, 141-151.
14. Greenwood FC, Hunter WM, Glover JS. (1963). The preparation of 131-I labelled human growth hormone of high specific radioactivity. Biochem J, 89, 114-123.
15. Hägg M, Liljegren Å, Carlsson J, Rönnstrand L, Lennartsson J. (2002). EGF and dextran-conjugated EGF induces differential phosphorylation of the EGF receptor. Int J Mol Med, 10, 655-659.
16. Haigler HT, Maxfield FR, Willingham MC, Pastan I. (1980). Dansylcadaverine inhibits internalization of 125I-epidermal growth factor in BALB 3T3 cells. J Biol Chem, 225, 1239-1241.
17. Heldin C-H, Westermark B. (1999). Mechanism of action and in vivo role of platelet-derived growth factor. Physiol Rev, 79, 1283-1316.
18. Hermansson M, Funa K, Hartman M, Claesson-Welsh L, Heldin C-H, Westermark B, Nistér M. (1992). Platelet-derived growth factor and its receptors in human glioma tissue: Expression of messenger RNA and protein suggests the presence of autocrine and paracrine loops. Cancer Res, 52, 3213-3219.
19. Hermansson M, Funa K, Koopmann J, Maintz D, Waha A, Westermark B, Heldin C-H, Wiestler OD, von Deimling A, Nistér M. (1996). Association of loss of heterozygosity on chromosome 17p with high platelet-derived growth factor ? receptor expression in human malignant gliomas. Cancer Res, 56, 164-171.
20. Hunter SB, Brat DJ, Olson JJ, Von Diemling A, Zhou W, van Meir EG. (2003). Alterations in molecular pathways of diffusively infiltrating glial neoplasms: Application to tumor classification and anti-tumor therapy. Int J Oncol, 23, 857-869.
21. Kirsch M, Wilson JC, Black P. (1997). Platelet-derived growth factor in human brain tumors. J Neurooncol, 35, 289-301.
22. Kleihues P, Ohgaki H. (1999). Primary and secondary glioblastomas: From concept to clinical diagnosis. Neuro-oncology, 1, 44-51.
23. Kohn J, Wilchek M. (1983). 1-cyano-4-dimethylamino pyridinium tetra-fluoroborate as a cyanylating agent for the covalent attachment of ligand to polysaccharide resins. FEBS Lett, 154, 209-210.
24. Kohn J, Wilchek M. (1984). The use of cyanogen bromide and other novel cyanylating agents for the activation of polysaccharide resins. Appl Biochem Biotechnol, 9, 285-305.
25. Lassman AB. (2004). Molecular biology of gliomas. Curr Neurol Neurosci Rep, 4, 228-233.
26. Lokker NA, Sullivan CM, Hollenbach SJ, Israel MA, Giese NA. (2002). Platelet-derived growth factor (PDGF) autocrine signalling regulates survival and mitogenic pathways in glioblastoma cells: Evidence that the novel PDGF-C and PDGF-D ligands may play a role in development of brain tumors. Cancer Res, 62, 3729-3735.
27. Mehvar R. (2000). Dextrans for targeted and sustained delivery of therapeutic and imaging agents. J Control Release, 69, 1-25.
28. Molteni L. (1979). Dextrans as drug carriers. In: Gregoriadis G. (Ed.), Drug Carriers in Biology and Medicine (pp. 107-125). Chapter 6. London: Academic Press.
29. Nistér M, Wedell B, Betsholtz C, Bywater M, Pettersson M, Westermark B, Mark J. (1987). Evidence for progressional changes in the human malignant glioma cell line U343MGa: Analysis of karyotype and expression of genes encoding the subunit chains of platelet-derived growth factor. Cancer Res, 47, 4953-4960.
30. Nistér M, Libermann TA, Betsholtz C, Pettersson M, Claesson- Welsh L, Heldin C-H, Schlessinger J, Westermark B. (1988). Expression of messenger RNAs for platelet-derived growth factor and transforming growth factor-alpha and their receptors in human malignant glioma cell lines. Cancer Res, 48, 3910-3918.
31. Nistér M, Claesson-Welsh L, Eriksson A, Heldin C-H, Westermark B. (1991). Differential expression of platelet-derived growth factor receptors in human malignant glioma cell lines. J Biol Chem, 266, 16755-16763.
32. Pietras K, Sjöblom T, Rubin K, Heldin C-H, Östman A. (2003). PDGF receptors as cancer drug targets. Cancer Cell, 3, 439-443.
33. Pontén J, Westermark B. (1978). Properties of human malignant glioma cells in vitro. Med Biol, 56, 184-193.
34. Rich JN, Bigner DD. (2004). Development of novel targeted therapies in the treatment of malignant glioma. Nat Rev Drug Discov, 3, 430-446.
35. Sathornsumetee S, Rich J. (2006). New approaches to primary brain tumor treatment. Anticancer Drugs, 17, 1003-1016.
36. Shapiro JR, Mehta BM, Ebrahim SAD, Scheck AC, Moots PL, Fiola MR. (1991). Tumor heterogeneity and intrinsically chemoresistant subpopulations in freshly resected malignant gliomas. In: Sudilovsky O. et al. (Eds.), Boundaries between Promotion and Progression during Carcinogenesis (pp. 243-262). New York: Plenum Press.
37. Sjöström A, Bue P, Malmström P-U, Nilsson S, Carlsson J. (1997). Binding, internalization and degradation of EGF-dextran conjugates in two human bladder cancer cell lines. Int J Cancer, 70, 383-389.
38. Westermark B. (1993). PDGF and its receptor in human tumor cells. In: Westermark B, Sorg C. (Eds.), Biology of Platelet-Derived Growth Factor (pp. 146-162). Vol.5. Basel: Karger.
39. Westermark B, Magnusson A, Heldin C-H. (1982). Effect of epidermal growth factor on membrane motility and cell locomotion in cultures of human clonal glioma cells. J Neurosci Res, 8, 491-507.
40. Westermark B, Heldin C-H, Nistér M. (1995). Platelet-derived growth factor in human glioma. Glia, 15, 257-263.
41. Wong MLH, Kaye AH, Hovens CM. (2007). Targeting malignant glioma survival signalling to improve clinical outcomes. J Clin Neurosci, 14, 301-308.
42. Zalipsky S, Lee C. (1992). Use of functionalized poly(ethylene glycols) for modification of polypeptides. In: Milton Harris J. (Ed.), Poly(ethylene glycol) Chemistry: Biotechnical and Biomedical Applications (pp. 347-370). New York: Plenum Press.
43. Zhao Q, Gottschalk I, Carlsson J, Arvidsson L-E, Oscarsson S, Medin A, Ersson B, Janson J-C. (1997). Preparation and purification of an end to end coupled mEGF-dextran conjugate. Bioconjugate Chem, 8, 927-934.